What is Zacks Research's Estimate for Chemours Q4 Earnings?

The Chemours Company (NYSE:CC - Free Report) - Equities researchers at Zacks Research cut their Q4 2024 earnings estimates for Chemours in a research note issued to investors on Tuesday, January 14th. Zacks Research analyst R. Department now expects that the specialty chemicals company will post earnings of $0.10 per share for the quarter, down from their prior estimate of $0.18. The consensus estimate for Chemours' current full-year earnings is $1.21 per share. Zacks Research also issued estimates for Chemours' Q1 2025 earnings at $0.51 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $2.01 EPS, Q2 2026 earnings at $0.78 EPS, Q3 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.42 EPS and FY2026 earnings at $2.43 EPS.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.32 by $0.08. The firm had revenue of $1.50 billion during the quarter, compared to analysts' expectations of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company's revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.64 earnings per share.

Other equities research analysts have also recently issued research reports about the company. The Goldman Sachs Group reduced their price objective on Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a report on Tuesday, January 7th. Barclays boosted their price target on Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Morgan Stanley lowered their price objective on Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday. BMO Capital Markets lifted their target price on Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, October 7th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $25.00 price target on shares of Chemours in a research note on Thursday, December 12th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $23.75.

Chemours Stock Performance

CC traded up $0.32 on Thursday, reaching $19.11. The company had a trading volume of 892,892 shares, compared to its average volume of 1,633,419. The stock has a market cap of $2.85 billion, a P/E ratio of 38.21 and a beta of 1.83. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. Chemours has a fifty-two week low of $15.10 and a fifty-two week high of $32.48. The company's fifty day moving average is $19.17 and its 200 day moving average is $19.79.

Hedge Funds Weigh In On Chemours

A number of institutional investors have recently modified their holdings of the business. Blue Trust Inc. boosted its stake in Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after buying an additional 731 shares in the last quarter. Matrix Trust Co bought a new position in shares of Chemours in the third quarter worth about $25,000. GAMMA Investing LLC boosted its stake in shares of Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 765 shares in the last quarter. Truvestments Capital LLC bought a new stake in shares of Chemours during the 3rd quarter valued at approximately $35,000. Finally, Brooklyn Investment Group acquired a new position in Chemours during the 3rd quarter worth approximately $37,000. Institutional investors and hedge funds own 76.26% of the company's stock.

Insiders Place Their Bets

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the company's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the sale, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.47% of the company's stock.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.00 annualized dividend and a yield of 5.23%. Chemours's dividend payout ratio is 200.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.